ReviewFrontiers in immunology2016
Antimicrobial Proteins and Peptides in Early Life: Ontogeny and Translational Opportunities.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Systems biology approaches to unravelling neonatal sepsis and potential for precision diagnostics and therapeutics.Frontiers in pharmacology · 2026Review
- Molecular Characterization, Expression Responses and Antipathogenic Bacterial Function of Interleukin-1β (IL-1β) in Asian Seabass (Biomolecules · 2025Article
- Dynamic Variations in Endogenous Peptides in Chinese Human Milk Across Lactation and Geographical Regions.Nutrients · 2025Article
- Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.Viruses · 2025Review
- Characterization and virulence of yeasts associated with neonatal thrush.BMC microbiology · 2025Article
- Bactericidal/Permeability-Increasing Protein (BPI), a Novel Antimicrobial Molecule in Human Breast Milk with Immune Potential.Microorganisms · 2025Article
- Skin Barrier Function in Neonates and Infants.Allergy, asthma & immunology research · 2025Review
- Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.Physiological reviews · 2024Review
- Antimicrobial Peptides (AMPs) and the Microbiome in Preterm Infants: Consequences and Opportunities for Future Therapeutics.International journal of molecular sciences · 2024Review
- Concentration of novel urinary tract infection biomarkers in neonates.Scientific reports · 2024Article
- The Nonbacterial Microbiome: Fungal and Viral Contributions to the Preterm Infant Gut in Health and Disease.Microorganisms · 2023Review
- Maternal thyroid peroxidase antibody positivity and its association with incidence of low birth weight in infants.Frontiers in endocrinology · 2023Article
- Antimicrobial skin peptides in premature infants: Comparison with term infants and impact of perinatal factors.Frontiers in immunology · 2023Article
- Review
- Antimicrobial peptides with cell-penetrating activity as prophylactic and treatment drugs.Bioscience reports · 2022Review
- Detecting the Mechanism of Action of Antimicrobial Peptides by Using Microscopic Detection Techniques.Foods (Basel, Switzerland) · 2022Review
- Antimicrobial Peptides in Early-Life Host Defense, Perinatal Infections, and Necrotizing Enterocolitis-An Update.Journal of clinical medicine · 2022Review
- The role of artificial intelligence in the battle against antimicrobial-resistant bacteria.Current genetics · 2021Review
- Article
- [Effect of Bifidobacterium on the expression of β-defensin-2 in intestinal tissue of neonatal rats with necrotizing enterocolitis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
Abstract
While developing adaptive immune responses, young infants are especially vulnerable to serious infections, including sepsis, meningitis, and pneumonia. Antimicrobial proteins and peptides (APPs) are key effectors that function as broad-spectrum anti-infectives. This review seeks to summarize the clinically relevant functional qualities of APPs and the increasing clinical trial evidence for their use to combat serious infections in infancy. Levels of APPs are relatively low in early life, especially in infants born preterm or with low birth weight (LBW). There are several rationales for the potential clinical utility of APPs in the prevention and treatment of infections in infants: (a) APPs may be most helpful in those with reduced levels; (b) during sepsis microbial products signal via pattern recognition receptors causing potentially harmful inflammation that APPs may counteract; and (c) in the era of antibiotic resistance, development of new anti-infective strategies is essential. Evidence supports the potential clinical utility of exogenous APPs to reduce infection-related morbidity in infancy. Further studies should characterize the ontogeny of antimicrobial activity in mucosal and systemic compartments, and examine the efficacy of exogenous-APP formulations to inform translational development of APPs for infant groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.